Diacerein. A controversial EU re-evaluation upholds marketing authorisation, unfortunately.
Some national health authorities were in favour of market withdrawal of diacerein, a "slow-acting symptomatic" treatment for osteoarthritis, because of a disproportionate risk of adverse effects.
D000880:Anthraquinones / Q000009:adverse effects*; D000893:Anti-Inflammatory Agents / Q000009:adverse effects*; D017277:Drug Approval; D005060:Europe; D006801:Humans; D015207:Osteoarthritis, Hip / Q000175:diagnosis / Q000188:drug therapy*; D020370:Osteoarthritis, Knee / Q000175:diagnosis / Q000188:drug therapy*; D061214:Patient Safety; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
D000880:Anthraquinones; D000893:Anti-Inflammatory Agents; C025292:diacerein